Extrait

- To evaluate the efficacy and dose response of M2951 compared to placebo in reducing disease activity in adult subjects with active, autoantibody-positive SLE who are receiving SoC therapy based on SRI-4 response at Week 52 in all subjects, or on SRI-6 response at Week 52 in the HDA subgroup, defined as SLEDAI-2K ≥ 10. - To evaluate the safety of M2951 in subjects with SLE on SoC therapy.

Critère d'inclusion

• Systemic lupus erythematosus (SLE)

Liens

• euctr